Clinical trial
A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal…
NCT00162110 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00162110 |
|---|---|
| Title | A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces |
| Official title | A Phase II Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mucinous Gastrointestinal Adenocarcinoma |
| Intervention type | Drug |
| Interventions | cetuximab |
| Enrollment | 40 |
| Start date | Nov 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Sep 13, 2005 |
| Last update posted | Oct 28, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: